The Income Tax Appellate Tribunal, Mumbai, has delivered a significant ruling clarifying the tax treatment of trade margins in pharmaceutical distribution, the timing of tax deduction on Employee Stock Option Plans, and the applicability of TDS on interest paid to MSMEs. The decision reinforces statutory interpretation over commercial assumptions and provides critical guidance for multinational healthcare companies operating in India.
Background & Facts
The Dispute
The appellant, Novartis Healthcare Pvt. Ltd., is a pharmaceutical company engaged in the manufacture and distribution of healthcare products through a network of stockists and distributors. The Income Tax Department initiated proceedings under Section 201(1) and 201(1A) of the Income Tax Act, 1961, alleging that the company failed to deduct tax at source (TDS) on three distinct payments: (1) trade margins earned by stockists, (2) the accounting recognition of Employee Stock Option Plans (ESOPs), and (3) interest paid on delayed payments to Micro, Small and Medium Enterprises (MSMEs). The Assessing Officer (AO) treated these as taxable payments under Sections 194H, 192, and 194A respectively, and raised demands for TDS shortfalls along with interest.
Key Facts
- The appellant sells pharmaceutical products to stockists at agreed invoice prices, which are lower than the Maximum Retail Price (MRP).
- Stockists independently resell the products to retailers, bearing all risks of inventory, pricing, and market demand.
- GST is charged by the appellant on invoices issued to stockists, and stockists account for these purchases in their books as inventory.
- The appellant’s agreements with stockists include quality control, territory restrictions, and sales targets, all aligned with regulatory requirements under the Medical Council of India.
- ESOPs were granted to employees during the relevant assessment years (2015-16 and 2017-18), but no options were exercised during those years.
- The appellant recognized accounting expenditure for ESOPs in its financial statements during the vesting period.
- The appellant made delayed payments to MSME suppliers, attracting liability under the MSMED Act, 2006.
- The appellant voluntarily disallowed the interest amount under Section 37(1) while filing its income tax returns.
- No separate commission payments were made by the appellant to stockists.
Procedural History
- 2015-16 and 2017-18: Assessment years under scrutiny.
- 2019-2020: Notices issued under Section 201(1) by the Assessing Officer.
- 2020: AO issued orders treating trade margins as commission (Section 194H), ESOP recognition as taxable event (Section 192), and MSME interest as taxable interest (Section 194A).
- 2021: First appellate authority (CIT(A)) dismissed the AO’s demands on all three issues.
- 2022-2023: Revenue filed appeals before the ITAT, Mumbai, against the CIT(A)’s order.
- 2024: Coordinate bench of ITAT Mumbai, in assessee’s own case for A.Y. 2020-21 and 2021-22, ruled in favor of the assessee on identical issues.
- 11.05.2026: Hearing before the present bench.
- 27.05.2026: Judgment pronounced.
The Parties' Positions
For the Revenue
- Argued that trade margins retained by stockists were commission under Section 194H, as the appellant exercised control over pricing and distribution.
- Contended that ESOP expenditure recognized in books triggered TDS liability under Section 192 at the time of grant, not exercise.
- Asserted that interest under the MSMED Act constituted "interest" under Section 2(28A) and thus attracted TDS under Section 194A.
- Claimed the appellant was an "assessee in default" under Section 201(1) for non-deduction.
For the Assessee
- Maintained that transactions with stockists were principal-to-principal sales, not agency arrangements.
- Argued that Section 17(2)(vi) and CBDT Circular No. 9/2007 clearly link taxable perquisite to exercise of option, not grant.
- Stated that MSMED interest is compensation for delayed payment of goods, not interest on borrowed money.
- Highlighted voluntary disallowance under Section 37(1) negated any claim of default under Section 201.
Relief Sought
The Revenue sought to uphold the AO’s demands for TDS shortfalls and interest under Section 201(1A). The assessee sought confirmation of the CIT(A)’s order and dismissal of the Revenue’s appeals. The assessee also filed cross objections to reinforce the favorable findings.
The Legal Issue
The central questions were: (1) Whether trade margins earned by pharmaceutical stockists constitute "commission" under Section 194H; (2) Whether tax deduction under Section 192 arises at the time of grant or exercise of ESOPs; and (3) Whether interest payable under the MSMED Act qualifies as "interest" under Section 2(28A), thereby attracting TDS under Section 194A.
Arguments Presented
For the Appellant
The appellant relied on the statutory language of Section 17(2)(vi), which explicitly states that the taxable value of ESOPs is determined on the date of exercise, not grant. It cited CBDT Circular No. 9/2007, which clarifies that tax liability arises only when the benefit is actually availed. For trade margins, it emphasized that Section 194H requires a payment of commission or brokerage by the payer, which was absent here. The appellant pointed to judicial precedents including Piramal Healthcare Ltd. and Wockhardt Ltd., where coordinate benches held that regulatory controls do not convert sales into agency relationships. Regarding MSME interest, it argued that Section 2(28A) defines interest as payable in respect of "moneys borrowed," and delay in payment of goods does not constitute borrowing.
For the Respondent
The Revenue contended that the appellant’s control over pricing, territory, and inventory indicated an agency relationship, making margins commission under Section 194H. It argued that accounting recognition of ESOP expense in the books created an accrual of income, triggering TDS under Section 192. For MSME interest, it relied on the MSMED Act’s use of the term "interest," asserting that statutory labels override economic substance. It further claimed that voluntary disallowance under Section 37(1) did not absolve the assessee of statutory TDS obligations.
The Court's Analysis
The Tribunal conducted a rigorous analysis of statutory language, commercial realities, and binding precedents. On the issue of trade margins, the Tribunal rejected the Revenue’s agency theory, observing that "regulatory controls are inherent in pharmaceutical distribution to ensure compliance with safety standards and cannot be equated with control over commercial outcomes." It noted that the appellant received sale proceeds, not commission payments, and that stockists accounted for purchases and sales independently in their books.
"The appellant company was receiving sale price and not paying to stockist. In view of the above detailed discussion and by respectfully following the decisions of Hon'ble Jurisdictional High Court and Coordinate Benches in similar circumstances, the Bench decides that appellant company need not deduct TDS as TDS provisions are not applicable."
On ESOPs, the Tribunal emphasized the distinction between accounting treatment and taxability. It held that Section 17(2)(vi) is a charging provision and must be strictly construed. The Explanation to the provision explicitly ties taxation to the date of exercise, not grant. The Tribunal dismissed the Revenue’s reliance on book entries, stating that "accounting recognition does not equate to accrual of taxable income under the Income Tax Act."
Regarding MSME interest, the Tribunal distinguished between contractual compensation and interest on debt. It held that Section 2(28A) requires a lending-borrowing relationship, which was absent. The Tribunal further held that once the assessee voluntarily disallowed the expenditure under Section 37(1), there could be no "assessee in default" under Section 201(1), as no taxable income remained to be subject to TDS.
The Tribunal also applied the doctrine of consistency, noting that identical issues had been decided in the assessee’s favor for A.Y. 2020-21 and 2021-22, and no distinguishing facts were presented to justify departure from precedent.
The Verdict
The appeals filed by the Revenue are dismissed. The cross objections filed by the assessee are allowed. The orders of the CIT(A) are upheld. The appellant is not liable for TDS under Section 194H on trade margins, under Section 192 on ESOP grants, or under Section 194A on MSME delay interest. Consequently, the interest levied under Section 201(1A) is cancelled. The appellant is entitled to a refund of any TDS amounts already paid under protest, and no further demand shall be raised on these grounds.
What This Means For Similar Cases
Trade Margins Are Not Commission
- Practitioners must argue that any control exercised by a manufacturer over distributors for regulatory compliance does not create an agency relationship under Section 194H.
- The burden shifts to the Revenue to prove actual payment of commission, not mere pricing control.
- Pharmaceutical, FMCG, and medical device companies can rely on this precedent to defend distributor margin structures.
ESOP Taxation Is Triggered Only on Exercise
- Companies must not deduct TDS under Section 192 at the time of ESOP grant or vesting.
- Tax liability arises only when shares are allotted upon exercise, and the FMV is determined on that date.
- Accounting entries for ESOP expenses should not be used by Assessing Officers to trigger TDS.
MSME Interest Is Not TDS-able Under Section 194A
- Delayed payment penalties under the MSMED Act are not interest under Section 2(28A) and do not attract TDS.
- Voluntary disallowance under Section 37(1) precludes any claim of "assessee in default" under Section 201.
- Tax advisors should advise clients to formally disallow such amounts in returns to avoid litigation.
